Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8912311
SERIAL NO

13864096

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CLAUSEN HENRIKSTRANDVEJEN 70 HELLERUP 2900
MANDEL ULLASTRANDVEJEN 70 HELLERUP 2900

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Burchell, Joy London, GB 10 88
Clausen, Henrik Holte, DK 83 1003
Mandel, Ulla Holte, DK 9 54
Sørensen, Anne Louise Copenhagen S, DK 5 30
Tarp, Mads Agervig Kgs. Lyngby, DK 5 42
Taylor-Papadimitriou, Joyce London, GB 14 106

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 16, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00